Crinetics Pharmaceuticals Inc’s recently made public that its Chief Scientific Officer Betz Stephen F. unloaded Company’s shares for reported $3.14 million on Jun 12 ’25. In the deal valued at $32.23 per share,97,483 shares were sold. As a result of this transaction, Betz Stephen F. now holds 99,713 shares worth roughly $3.11 million.
Then, STEPHEN BETZ bought 97,483 shares, generating $3,151,625 in total proceeds.
Before that, Pizzuti Dana sold 2,515 shares. Crinetics Pharmaceuticals Inc shares valued at $86,021 were divested by the Chief Med and Dev Officer at a price of $34.20 per share. As a result of the transaction, Pizzuti Dana now holds 72,233 shares, worth roughly $2.25 million.
Stifel initiated its Crinetics Pharmaceuticals Inc [CRNX] rating to a Buy in a research note published on March 25, 2025; the price target was $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. Wolfe Research began covering CRNX with “Peer perform” recommendation on February 04, 2025. Jefferies revised its rating on January 22, 2025. It rated CRNX as “a Buy” which previously was an “a Hold”.
Price Performance Review of CRNX
On Monday, Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] saw its stock fall -1.79% to $31.20. Over the last five days, the stock has lost -3.35%. Crinetics Pharmaceuticals Inc shares have fallen nearly -38.98% since the year began. Nevertheless, the stocks have fallen -34.70% over the past one year. While a 52-week high of $62.53 was reached on 01/03/25, a 52-week low of $24.10 was recorded on 04/09/25.
Levels Of Support And Resistance For CRNX Stock
The 24-hour chart illustrates a support level at 30.75, which if violated will result in even more drops to 30.31. On the upside, there is a resistance level at 31.82. A further resistance level may holdings at 32.45.
The most recent change occurred on March 06, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $68 price target.
